Positron Emission Tomography Myocardial Perfusion Imaging for Diagnosis and Risk Stratification in Obese Patients

Current Cardiovascular Imaging Reports

Volumn 8, Issue 1, 2015, Pages 1-12

  Arasaratnam, Punitha ^a   Ayoub, Chadi ^a   Klein, Ran ^a   DeKemp, Rob ^a   Beanlands, Rob S ^a,b   Chow, Benjamin J W ^a,b  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Coronary artery disease; Diagnosis; Myocardial perfusion imaging; Obese; Positron emission tomography; Risk stratification

Indexed keywords

TRACER;

CARDIOVASCULAR DISEASE; CLINICAL EVALUATION; CORONARY ARTERY DISEASE; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; HEART FAILURE; HUMAN; META ANALYSIS; MYOCARDIAL PERFUSION IMAGING; OBESITY; POSITRON EMISSION TOMOGRAPHY; QUALITATIVE RESEARCH; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS;

EID: 84911966097     PISSN: 19419066     EISSN: 19419074     Source Type: Journal    
DOI: 10.1007/s12410-014-9304-y     Document Type: Review

References (78)

1. Organization WH. Physical Status: The Use and Interpretation of Anthropometry. Technical Report Series, No 854. Geneva: Switzerland; 1995.
2. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, Mullany EC, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014 [Epub ahead of print]. This is the most recent systematic analysis of the global prevalence of obesity.
3. Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes. 2008;32:1431–7.
4. National Institutes of Health NH, Lung, and Blood Institute and North American Association for the Study of Obesity. Practical Guide on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda: MD; 2000.
5. Pencina M, D’Agostino R, Fox C, Vasan R, Kannel W. Obesity is independently associated with long-term risk of cardiovascular mortality and underweight with risk of non-cardiovascular mortality in Framingham Offspring Cohort. Circulation. 2009;120. [Abstract 1466].
6. Kenchaiah S, Evans JC, Levy D, Wilson PWF, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347:305–13.
7. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. American Heart Association, Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association scientific statement on obesity and heart disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113:898–918.
8. Murphy NF, MacIntyre K, Stewart S, Hart CL, Hole D, McMurray JJV. Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15,000 middle-aged men and women (the Renfrew–Paisley study). Eur Heart J. 2006;27:96–106.
9. Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity. JAMA. 2003;289:187–93.
10. Badimon L, Hernandez Vera R, Vilahur G. Atherothrombotic risk in obesity. Hamostaseologie. 2013;33:259–68. This is a comprehensive review of the atherothrombotic risk in obesity.
11. Motivala AA, Rose PA, Kim HM, Smith YR, Bartnik C, Brook RD, et al. Cardiovascular risk, obesity, and myocardial blood flow in postmenopausal women. J Nucl Cardiol. 2008;15:510–7.
12. Sundell J, Raitakari OT, Viikari J, Kantola I, Nuutila P, Knuuti J. Both BMI and waist circumference are associated with coronary vasoreactivity in overweight and obese men. Obes Facts. 2012;5:693–9.
13. Al Suwaidi J, Higano ST, Holmes Jr DR, Lennon R, Lerman A. Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries. J Am Coll Cardiol. 2001;37:1523–8.
14. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101:948–54.
15. Machac J. Cardiac positron emission tomography imaging. Sem Nucl Med. 2005;35:17–36.
16. Machac J, Bacharach S, Bateman T, Bax J, Beanlands R, Bengel F, et al. Quality Assurance Committee of the American Society of Nuclear Cardiology. Positron emission tomography myocardial perfusion and glucose metabolism imaging. J Nucl Cardiol. 2006;13:e121–51.
17. Dilsizian V, Bacharach S, Beanlands R, Bergmann S, Delbeke D, Gropler RJ, et al. PET myocardial perfusion and metabolism clinical imaging. J Nucl Cardiol. 2009;16:651.
18. Groves A, Speechly-Dick M-E, Dickson J, Kayani I, Endozo R, et al. Cardiac 82rubidium PET/CT: initial European experience. Eur J Nucl Med Mol Imaging. 2007;34:1965–72.
19. Dhar R, Ananthasubramaniam K. Rubidium-82 Cardiac positron emission tomography imaging: an overview for the general cardiologist. Cardiol Rev. 2011;19:255–63.
20. Yu JN, Fahey FH, Harkness BA, Gage HD, Eades CG, Keyes JW. Evaluation of emission-transmission registration in thoracic PET. J Nucl Med. 1994;35:1777–80.
21. McCord ME, Bacharach SL, Bonow RO, Dilsizian V, Cuocolo A, Freedman N. Misalignment between PET transmission and emission scans: its effect on myocardial imaging. J Nucl Med. 1992;33:1209–14.
22. Loghin C, Sdringola S, Gould KL. Common artifacts in PET myocardial perfusion images due to attenuation–emission misregistration: clinical significance, causes, and solutions. J Nucl Med. 2004;45:1029–39.
23. Hu S, Liu S, Katus H, Leudde M. The value of contrast dobutamine stress echocardiography in detecting coronary artery disease in overweight and obese patients. Can J Cardiol. 2007;23:885–9.
24. Bhat G, Daley K, Dugan M, Larson G. Preoperative evaluation for bariatric surgery using transesophageal dobutamine stress echocardiography. Obes Surg. 2004;14:948–51.
25. Budoff MJ, Achenbach S, Blumenthal RS, Carr JJ, Goldin JG, Greenland P, et al. American Heart Association Council on Cardiovascular Imaging and Intervention, American Heart Association Committee on Cardiac Imaging. Assessment of Coronary Artery Disease by Cardiac Computed Tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging. Counc Clin Cardiol Circ. 2006;114:1761–91.
26. Labounty T, Gomez M, Achenbach S, Al-Mallah M, Berman D, Budoff M, et al. Body mass index and the prevalence, severity and risk of coronary artery disease: an international multicenter study of 13,874 patients. Eur Heart J Cardiovasc Imaging. 2013;14:456–63.
27. Shah RV, Heydari B, Coelho-Filho O, Abbasi SA, Feng JH, Neilan TG, et al. Vasodilator stress perfusion CMR imaging is feasible and prognostic in obese patients. JACC Cardiovasc Imaging. 2014;7:462–72. doi:10.1016/j.jcmg.2013.11.011. This was a recent study to examine the prognostic value of stress CMR in obese patients.
28. Miller J. Imaging obese patients. Radiol Rounds. 2011;4.
29. Ghanem MA, Kazim NA, Elgazzar AH. Impact of obesity on nuclear medicine imaging. J Nucl Med Technol. 2011;39:40–50.
30. Elhendy A, Schinkel AFL, van Domburg RT, Bax JJ, Valkema R, Biagini E, et al. Prognostic stratification of obese patients by stress 99mTc-Tetrofosmin myocardial perfusion imaging. J Nucl Med. 2006;47:1302–6.
31. Duvall WL, Croft LB, Corriel JS, Einstein AJ, Fisher JE, Haynes PS, et al. SPECT myocardial perfusion imaging in morbidly obese patients: image quality, hemodynamic response to pharmacologic stress, and diagnostic and prognostic value. J Nucl Cardiol. 2006;13:202–9.
32. Gimelli A, Bottai M, Giorgetti A, Genovesi D, Filidei E, Marzullo P. Evaluation of ischaemia in obese patients: feasibility and accuracy of a low-dose protocol with a cadmium-zinc telluride camera. Eur J Nucl Med Mol Imaging. 2012;39:1254–61.
33. Buschur ME, Smith D, Share D, Campbell W, Mattichak S, Sharma M, et al. The burgeoning epidemic of morbid obesity in patients undergoing percutaneous coronary intervention: insight from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. J Am Coll Cardiol. 2013;62:685–91. This study examined the morbidity and mortality rates after PCI in 227,044 obese patients.
34. McArdle BA, Dowsley TF, deKemp RA, Wells GA, Beanlands RS. Does rubidium-82 PET have superior accuracy to SPECT perfusion imaging for the diagnosis of obstructive coronary disease?: a systematic review and meta-analysis. J Am Coll Cardiol. 2012;60:1828–37.
35. Alhassen F, Nguyen N, Bains S, Gould RG, Seo Y, Bacharach SL, et al. Myocardial blood flow measurement with a conventional dual-head SPECT/CT with spatiotemporal iterative reconstructions—a clinical feasibility study. Am J Nucl Med Mol Imaging. 2013;4:53–9.
36. Yoshinaga K, Klein R, Tamaki N. Generator-produced rubidium-82 positron emission tomography myocardial perfusion imaging from basic aspects to clinical applications. J Cardiol. 2010;55:163–73.
37. Kaufmann PA, Camici PG. Myocardial blood flow measurement by PET: technical aspects and clinical applications. J Nucl Med. 2005;46:75–88.
38. Schindler TH, Schelbert HR, Quercioli A, Dilsizian V. Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health. JACC Cardiovasc Imaging. 2010;3:623–40.
39. Di Carli M, Hachamovitch R. Should PET replace SPECT for evaluating CAD? The end of the beginning. J Nucl Cardiol. 2006;13:2–7.
40. Aarnoudse WH, Botman KJ, Pijls NH. False-negative myocardial scintigraphy in balanced three-vessel disease, revealed by coronary pressure measurement. Int J Cardiovasc Intervent. 2003;5:67–71.
41. Kumar SP, Movahed A. Importance of wall motion analysis in the diagnosis of left main disease using stress nuclear myocardial perfusion imaging. Int J Cardiovasc Imaging. 2003;19:219–24.
42. Dorbala S, Vangala D, Sampson U, Limaye A, Kwong R, Di Carli MF. Value of vasodilator left ventricular ejection fraction reserve in evaluating the magnitude of myocardium at risk and the extent of angiographic coronary artery disease: a 82Rb PET/CT study. J Nucl Med. 2007;48:349–58.
43. Di Carli M, Czernin J, Hoh C, Gerbaudo V, Brunken R, Huang S, et al. Relation among stenosis severity, myocardial blood flow, and flow reserve in patients with coronary artery disease. Circulation. 1995;91:1944–51.
44. Uren N, Melin J, de Bruyne B, Wijns W, Baudhuin T, Camici P. Relation between myocardial blood flow and the severity of coronary-artery stenosis. N Engl J Med. 1994;330:1782–8.
45. Beanlands R, Muzik O, Melon P, Sutor R, Sawada S, Muller D, et al. Noninvasive quantification of regional myocardial flow reserve in stenosed and angiographically normal vessels of patients with coronary atherosclerosis. J Am Coll Cardiol. 1995;26:1465–75.
46. Hendel R, Berman DS, Di Carli MF, Heidenreich PA, Henkin RE, Pellikka PA, et al. American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Nuclear Cardiology, American College of Radiology, American Heart Association, American Society of Echocardiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, Society of Nuclear Medicine. ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009. Appropriate use criteria for cardiac radionuclide imaging: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear Cardiology, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine. Endorsed by the American College of Emergency Physicians. J Am Coll Cardiol. 2009;53:2201–29.
47. Sampson U, Dorbala S, Limaye A, Kwong R, Di Carli M. Diagnostic accuracy of rubidium-82 myocardial perfusion imaging with hybrid positron emission tomography/computed tomography in the detection of coronary artery disease. J Am Coll Cardiol. 2007;49:1052–8.
48. Freedman N, Schechter D, Klein M, Marciano R, Rozenman Y, Chisin R. SPECT attenuation artifacts in normal and overweight persons: insights from a retrospective comparison of Rb-82 positron emission tomography and TI-201 SPECT myocardial perfusion imaging. Clin Nucl Med. 2000;25:1019–23.
49. Bateman TM, Heller GV, McGhie AI, Friedman JD, Case JA, Bryngelson JR, et al. Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG-gated Tc-99m sestamibi SPECT. J Nucl Cardiol. 2006;13:24–33.
50. Hachamovitch R, Berman DS. The use of nuclear cardiology in clinical decision making. Semin Nucl Med. 2005;35:62–72.
51. Hachamovitch R, Shaw L, Berman DS. Methodological considerations in the assessment of noninvasive testing using outcomes research: pitfalls and limitations. Prog Cardiovasc Dis. 2000;43:215–30.
52. Beller G, Zaret B. Contributions of nuclear cardiology to diagnosis and prognosis of patients with coronary artery disease. Circulation. 2000;101:1465–78.
53. Yoshinaga K, Chow BJ, Williams K, Chen L, dekemp RA, Garrard L, et al. What is the prognostic value of myocardial perfusion imaging using rubidium-82 positron emission tomography? J Am Coll Cardiol. 2006;48:1029–39.
54. Berman DS, Hachamovitch R, Kiat H, Cohen I, Cabico JA, Wang FP, et al. Incremental value of prognostic testing in patients with known or suspected ischemic heart disease: a basis for optimal utilization of exercise technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography. J Am Coll Cardiol. 1995;26:639–47.
55. MacIntyre WJ, Go RT, King JL, Cook SA, Neumann DR, Saha GB, et al. Clinical outcome of cardiac patients with negative thallium-201 SPECT and positive rubidium-82 PET myocardial perfusion imaging. J Nucl Med. 1993;34:400–4.
56. Klodas E, Miller T, Christian T, Hodge D, Gibbons R. Prognostic significance of ischemic electrocardiographic changes during vasodilator stress testing in patients with normal SPECT images. J Nucl Cardiol. 2003;10:4–8.
57. Chow B, Wong J, Yoshinaga K, Ruddy T, Williams K, deKemp R, et al. Prognostic significance of dipyridamole-induced ST depression in patients with normal 82Rb PET myocardial perfusion imaging. J Nucl Med. 2005;46:1095–101.
58. Chow BJW, Dorbala S, Di Carli MF, Merhige ME, Williams BA, Veledar E, et al. Prognostic value of PET myocardial perfusion imaging in obese patients. JACC Cardiovasc Imaging. 2014;7:278–87. This was the largest multi-center observational registry to date to evaluate the prognostic value of PET MPI in obese patients.
59. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010;56:e50–e103.
60. Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM, McAlister FA. Body mass index and mortality in heart failure: a meta-analysis. Am Heart J. 2008;156:13–22.
61. Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG, et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet. 2006;368:666–78.
62. Uretsky S, Messerli FH, Bangalore S, Champion A, Cooper-Dehoff RM, Zhou Q, et al. Obesity paradox in patients with hypertension and coronary artery disease. Am J Med. 2007;120:863–70.
63. McAuley PA, Kokkinos PF, Oliveira RB, Emerson BT, Myers JN. Obesity paradox and cardiorespiratory fitness in 12,417 male veterans aged 40 to 70 years. Mayo Clin Proc. 2010;85:115–21.
64. Lertsburapa K, Ahlberg AW, Bateman TM, Katten D, Volker L, Cullom SJ, et al. Independent and incremental prognostic value of left ventricular ejection fraction determined by stress gated rubidium 82 PET imaging in patients with known or suspected coronary artery disease. J Nucl Cardiol. 2008;15:745–53.
65. Dorbala S, Hachamovitch R, Curillova Z, Thomas D, Vangala D, Kwong RY, et al. Incremental prognostic value of gated Rb-82 positron emission tomography myocardial perfusion imaging over clinical variables and rest LVEF. JACC Cardiovasc Imaging. 2009;2:846–54.
66. Barbosa JA, Rodrigues AB, Mota CC, Barbosa MM, Simões e Silva AC. Cardiovascular dysfunction in obesity and new diagnostic imaging techniques: the role of noninvasive image methods. Vasc Health Risk Manag. 2011;7:287–95.
67. Alpert M, Terry BE, Mulekar M, Cohen MV, Massey CV, Fan TM, et al. Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure, and effect of weight loss. Am J Cardiol. 1997;80:736–40.
68. Lavie CJ, Alpert MA, Arena R, Mehra MR, Milani RV, Ventura HO. Impact of obesity and the obesity paradox on prevalence and prognosis in heart-failure. JACC Heart Fail. 2013;1:93–102. This state of the art paper examined the association between obesity and heart failure.
69. Gewirtz H. Cardiac PET: a versatile, quantitative measurement tool for heart failure management. JACC Cardiovasc Imaging. 2011;4:292–302.
70. Beanlands RS, Nichol G, Huszti E, Humen D, Racine N, Freeman M, et al. PARR-2 Investigators. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol. 2007;50:2002–12.
71. Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, et al. STICH Trial Investigators. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med. 2011;364:1617–25.
72. Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici P. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med. 2003;349:1027–35.
73. Neglia D, Michelassi C, Trivieri MG, Sambuceti G, Giorgetti A, Pratali L, et al. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation. 2002;105:186–93.
74. Huggins GS, Pasternak RC, Alpert NM, Fischman AJ, Gewirtz H. Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse. Circulation. 1998;98:1291–6.
75. Peterson LR, Soto PF, Herrero P, Mohammed BS, Avidan MS, Schechtman KB, et al. Impact of gender on the myocardial metabolic response to obesity. JACC Cardiovasc Imaging. 2008;1:424–33.
76. Livingston EH, Langert J. The impact of age and Medicare status on bariatric surgical outcomes. Arch Surg. 2006;141:1115–20. discussion 21.
77. Livingston EH, Arterburn D, Schifftner TL, Henderson WG, DePalma RG. National Surgical Quality Improvement Program analysis of bariatric operations: modifiable risk factors contribute to bariatric surgical adverse outcomes. J Am Coll Surg. 2006;203:625–33.
78. Morino M, Toppino M, Forestieri P, Angrisani L, Allaix ME, Scopinaro N. Mortality after bariatric surgery: analysis of 13,871 morbidly obese patients from a national registry. Ann Surg. 2007;246:1002–7. discussion 7–9.